Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
595 public companies · 595 exchange-listed
595
Total Companies
595
Exchange Listed
487
Filed 10-K
43
States Represented
Total Sector Revenue
$586.46B
Aggregate of 311 companies with XBRL data
Avg Net Margin
-68.9%
Intensely competitive· Based on 311 filings
Sector Analysis · Sprytne.com
As of March 2026, the Pharmaceutical Preparations sector (SIC 2834) reports a combined revenue of $586.46B across 311 SEC-tracked entities. With an average net margin of -68.9%, this industry is classified as loss-making on average. JOHNSON & JOHNSON leads the sector with $94.19B in reported revenue. The data is derived exclusively from official SEC EDGAR XBRL submissions and reflects the most recently filed 10-K annual reports.
Data aggregated from SEC EDGAR XBRL submissions · Updated March 2026
| Rank | Company | Revenue | Net Income | Net Margin | vs Industry Avg |
|---|---|---|---|---|---|
| #1 | JOHNSON & JOHNSONJNJ | $94.19B | $26.80B | 28.5% | +97.4pp |
| #2 | ELI LILLY & CoLLY | $65.18B | $20.64B | 31.7% | +100.6pp |
| #3 | Merck & Co., Inc.MRK | $65.01B | $18.25B | 28.1% | +97.0pp |
| #4 | AbbVie Inc.ABBV | $61.16B | $4.23B | 6.9% | +75.8pp |
| #5 | PFIZER INCPFE | $50.91B | $7.77B | 15.3% | +84.2pp |
| Industry Average | $1.89B | $286.3M | -68.9% | baseline | |
60 DEGREES PHARMACEUTICALS, INC.
CIK: 0001946563 · DE · 10-K: 2025-03-27
Aardvark Therapeutics, Inc.
CIK: 0001774857 · DE · 10-K: 2026-03-23
ABBOTT LABORATORIES
CIK: 0000001800 · IL · 10-K: 2026-02-20
AbbVie Inc.
CIK: 0001551152 · DE · 10-K: 2026-02-20
AbCellera Biologics Inc.
CIK: 0001703057 · A1 · 10-K: 2026-02-24
ABEONA THERAPEUTICS INC.
CIK: 0000318306 · DE · 10-K: 2026-03-17
Abivax S.A.
CIK: 0001956827 · I0
ABVC BIOPHARMA, INC.
CIK: 0001173313 · NV · 10-K: 2026-03-03
AC Immune SA
CIK: 0001651625 · V8
ACADIA PHARMACEUTICALS INC
CIK: 0001070494 · DE · 10-K: 2026-02-26
Accustem Sciences Inc.
CIK: 0001850767 · DE · 10-K: 2025-04-03
Aclaris Therapeutics, Inc.
CIK: 0001557746 · DE · 10-K: 2026-02-26
Acrivon Therapeutics, Inc.
CIK: 0001781174 · · 10-K: 2026-03-19
Actinium Pharmaceuticals, Inc.
CIK: 0001388320 · DE · 10-K: 2025-03-31
ACTUATE THERAPEUTICS, INC.
CIK: 0001652935 · DE · 10-K: 2025-03-13
Acurx Pharmaceuticals, Inc.
CIK: 0001736243 · DE · 10-K: 2026-03-12
Adagene Inc.
CIK: 0001818838 · E9
Adastra Holdings Ltd.
CIK: 0001891512 · A1
ADC Therapeutics SA
CIK: 0001771910 · V8 · 10-K: 2026-03-10
Addex Therapeutics Ltd.
CIK: 0001574232 · V8
ADIAL PHARMACEUTICALS, INC.
CIK: 0001513525 · DE · 10-K: 2026-03-05
Adicet Bio, Inc.
CIK: 0001720580 · DE · 10-K: 2026-03-12
Aditxt, Inc.
CIK: 0001726711 · DE · 10-K: 2025-03-31
Adlai Nortye Ltd.
CIK: 0001944552 · DE
AEON Biopharma, Inc.
CIK: 0001837607 · DE · 10-K: 2025-03-24
AGIOS PHARMACEUTICALS, INC.
CIK: 0001439222 · DE · 10-K: 2026-02-12
Ainos, Inc.
CIK: 0001014763 · TX · 10-K: 2025-03-07
Akari Therapeutics Plc
CIK: 0001541157 · X0 · 10-K: 2025-04-15
Akebia Therapeutics, Inc.
CIK: 0001517022 · DE · 10-K: 2026-02-26
Aktis Oncology, Inc.
CIK: 0002035832 · DE
Alaunos Therapeutics, Inc.
CIK: 0001107421 · DE · 10-K: 2025-03-31
Aldeyra Therapeutics, Inc.
CIK: 0001341235 · DE · 10-K: 2026-02-27
Algernon Health Inc.
CIK: 0001642178 · A1
Alkermes plc.
CIK: 0001520262 · · 10-K: 2026-02-25
Allarity Therapeutics, Inc.
CIK: 0001860657 · DE · 10-K: 2025-03-31
ALNYLAM PHARMACEUTICALS, INC.
CIK: 0001178670 · · 10-K: 2026-02-12
Altamira Therapeutics Ltd.
CIK: 0001601936 · D0
ALTERITY THERAPEUTICS LTD
CIK: 0001131343 · C3
Altimmune, Inc.
CIK: 0001326190 · DE · 10-K: 2026-03-06
Alto Neuroscience, Inc.
CIK: 0001999480 · DE · 10-K: 2026-03-16
ALUMIS INC.
CIK: 0001847367 · DE · 10-K: 2026-03-19
ALX ONCOLOGY HOLDINGS INC
CIK: 0001810182 · DE · 10-K: 2026-03-09
Alzamend Neuro, Inc.
CIK: 0001677077 · DE · 10-K: 2025-07-22
AMARIN CORP PLC\UK
CIK: 0000897448 · X0 · 10-K: 2026-03-02
AMICUS THERAPEUTICS, INC.
CIK: 0001178879 · DE · 10-K: 2026-02-20
Amneal Pharmaceuticals, Inc.
CIK: 0001723128 · · 10-K: 2026-02-27
Amphastar Pharmaceuticals, Inc.
CIK: 0001297184 · · 10-K: 2026-02-26
Amylyx Pharmaceuticals, Inc.
CIK: 0001658551 · DE · 10-K: 2026-03-03
AN2 Therapeutics, Inc.
CIK: 0001880438 · DE · 10-K: 2026-03-17
ANAPTYSBIO, INC
CIK: 0001370053 · DE · 10-K: 2026-03-03
Showing 50 of 595 companies in this sector